News
Osteoporosis & Bone HealthJournal of Bone and Mineral Research

Osteoporosis and Low Bone Mass Affect 54 Million U.S. Adults Over 50

April 12, 2023

A landmark NHANES-based study estimates 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass — more than half of all adults over 50.

Read the original article at Journal of Bone and Mineral Research

Kairos™'s Take

Kairos™'s perspective on this story

A study published in the Journal of Bone and Mineral Research used nationally representative NHANES data to estimate that 10.2 million adults aged 50 and older had osteoporosis at the femoral neck or lumbar spine, while another 43.4 million had low bone mass (osteopenia) at either site. Combined, that is 53.6 million people — roughly 54% of the entire U.S. population in that age group. The data make it clear that compromised bone health is not an edge case. It is the norm for aging Americans.

The study also highlighted a stark gender disparity: 15.4% of women over 50 had osteoporosis compared to 4.3% of men, and 51.4% of women had low bone mass versus 35.2% of men. These numbers underline a critical window — the years surrounding menopause — when hormonal shifts accelerate bone loss and early detection becomes most valuable.

Why This Matters for Midlife Health

The sheer scale of the problem reframes how we should think about bone health. With more than half of adults over 50 carrying some degree of bone deficit, the question shifts from "am I at risk?" to "how much risk am I carrying, and do I know about it?" Most of these 53.6 million people have no symptoms. Osteoporosis does not announce itself until a fracture happens, which is why population-level data like this reinforces the case for proactive screening — particularly during and after the menopausal transition when estrogen withdrawal drives the fastest phase of bone loss.

The Tracking Connection

Prevalence studies give us the macro picture. What they cannot do is tell any individual where they stand. That is where longitudinal tracking becomes essential. Platforms like Kairos™ let users log DXA results over time, monitor hormonal symptoms that correlate with bone loss, and bring organized data to their provider visits. When you can show a clinician a timeline — symptoms, lab values, scan results — the conversation shifts from reactive to strategic. Given that more than half the population over 50 is affected, the question is not whether tracking matters, but how early you start.

Ready to start tracking?

Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.

Get Started

More from the newsroom

Back to all articles